JNJ-7777120 explained

JNJ-7777120 was a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H₄ receptor.^[1] It has anti-inflammatory effects,^[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment of pruritus (itching).^[3] The drug was abandoned because of its short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.^[4]

See also

• VUF-6002

Notes and References

1. Jiang W, Lim HD, Zhang M, etal . Cloning and pharmacological characterization of the dog histamine H(4) receptor . Eur. J. Pharmacol. . 592. 1–3. 26–32. July 2008 . 18639542 . 10.1016/j.ejphar.2008.06.095 .
2. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L . Apr 2004 . A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties . Journal of Pharmacology and Experimental Therapeutics . 309 . 1. 404–13 . 14722321 . 10.1124/jpet.103.061754 . 8396875 .
3. Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL . Jan 2007 . Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus . Journal of Allergy and Clinical Immunology . 119 . 1. 176–83 . 17208599 . 10.1016/j.jaci.2006.08.034 .
4. Book: Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP . Histamine and Histamine Receptors in Health and Disease . 2017 . Clinical Development of Histamine H4 Receptor Antagonists . Handbook of Experimental Pharmacology . 241 . 301–320 . 28233185 . 10.1007/164_2016_130 . 978-3-319-58192-7 .